Have an appointment today and need to reach us? Email us at [email protected]

For all other contact information, visit our Contact Us page.

LMC Manna Research is recruiting volunteers who have Type 2 Diabetes and existing kidney disease to participate in a clinical research trial that will provide access to an investigational medication that may reduce the risk of kidney and heart health issues in the future.

It’s important to take your kidney’s health seriously. Up to 40% of patients with type 2 diabetes (T2D) have some degree of chronic kidney disease (CKD). For the majority of cases, the kidney damage is directly caused by poorly controlled diabetes. Diabetes remains the single leading cause of kidney failure requiring chronic dialysis treatment or kidney transplantation. Yet there remains a major unmet medical need to improve the treatment of CKD in patients with T2D. This is why it is so important that research studies like this be conducted. The ultimate goal is to find new treatment options for CKD in patients with T2D.

 

Study participants who satisfy applicable requirements will be compensated for their time and will receive products and supplies free of charge.

You may be eligible to participate in this study if you:

  • Have a diagnosis of Type 2 Diabetes with blood sugar levels that are not well controlled

  • Are at least 18 years of age

  • Have been told to have moderate to severe kidney disease

Think this may be a great opportunity for you? Speak with a research specialist at LMC Manna Research today! We are proud to be part of such an exciting time in research and medication development & advancement.  If you would like to learn more about how to participate in one of our clinical research programs for Type 2 Diabetes and kidney health, contact us by emailing [email protected]* or calling us at 1-833-323-JOIN (5646)*.

Best wishes to a future of improved health & wellness,

The Clinical Research Teams
LMC Manna Research

———

“Improving the health of Canadians today and tomorrow 

through clinical research.”